Case Studies, Pharmaceutical

Case Study – Unidose Nasal Spray Pump for Opioid Overdose

Although naloxone has long been available in injection format as a treatment for opioid overdose, administration relies on the presence of a suitably trained responder. This case study describes a collaborative drug repurposing project with Aptar Pharma to develop an easy-to-administer naloxone nasal spray. The resulting product has been successfully commercialized to broaden access to a life-saving therapeutic. Utilizing Aptar Pharma’s Unidose Liquid (UDS) system, it is primeless, reliable, and intuitive. Collaboration accelerated time to market for the nasal spray via the FDA’s 505(b)(2) Abbreviated Approval Pathway (U.S.) creating valuable intellectual property. The global market for the product is in excess of $350 million (2021).

Download Case Study - Unidose Nasal Spray pump for opioid overdose
8 Sep 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

5 Nov 2020

The Need to Scale Up Digital Health in the Post-Covid World

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
6 Oct 2020

Using Bioequivalence and Particle Size Distribution to Develop OINDPs

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
5 Oct 2020

Reusable systems and recyclable packaging aid pharma sustainability

Publications, Pharmaceutical, Sustainability, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
15 Jun 2020

Accelerating the development of COVID vaccines and therapeutics

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
1 18 19 20 21 22 25

Request Access

Close

Requesting access to Case Study – Unidose Nasal Spray Pump for Opioid Overdose.

  • This field is for validation purposes and should be left unchanged.
Back To Top